SAB Biotherapeutics completes dosing of cohort 3 for SAB-142 Phase 1 trial; no serum sickness observed

SAB Biotherapeutics, Inc.

Completed dosing of cohort 3 in Phase 1 trial of SAB-142.
No instances of serum sickness reported.
Company to issue corporate update press release on or about April 16, 2024.

item 7.01

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-044497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.